SurgiMab Overview

  • Year Founded
  • 2010

Year Founded

  • Status
  • Private

  • Employees
  • 6

Employees

  • Latest Deal Type
  • Later Stage VC

  • Latest Deal Amount
  • $16.3M

  • Investors
  • 2

SurgiMab General Information

Description

Operator of a biotechnology company intended to develop injectable fluorescent conjugates. The company integrates the molecular specificity of monoclonal antibodies with the high sensitivity of fluorescence-based intraoperative imaging, enabling healthcare providers to support earlier detection, make improved decision-making and offer effective treatment.

Contact Information

Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Corporate Office
  • 10, Parc Club du Millénaire
  • 1025, avenue Henri Becquerel
  • 34000 Montpellier
  • France
Primary Industry
Biotechnology
Other Industries
Drug Discovery
Vertical(s)
Corporate Office
  • 10, Parc Club du Millénaire
  • 1025, avenue Henri Becquerel
  • 34000 Montpellier
  • France

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

SurgiMab Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
4. Later Stage VC 01-Jan-2021 $16.3M Completed Clinical Trials - Phase 3
3. Accelerator/Incubator 01-Jan-2014 Completed Clinical Trials - Phase 1
2. Seed Round 01-Jan-2013 $10.9M $12.9M Completed Pre-Clinical Trials
1. Seed Round 21-Feb-2012 $1.97M $1.97M Completed Startup
To view SurgiMab’s complete valuation and funding history, request access »

SurgiMab Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion Price % Owned
Ordinary
To view SurgiMab’s complete cap table history, request access »

VC Exit Predictor

See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.

Opportunity Score

Calculated using Exit Type probabilities, the company’s stage, and PitchBook’s historical returns data.

Exit Type

Evaluates the likelihood of a successful exit for investors, and the most likely exit type.

SurgiMab Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Operator of a biotechnology company intended to develop injectable fluorescent conjugates. The company integrates the mo
Biotechnology
Montpellier, France
6 As of 2026

Ruffieux, France
 

San Diego, CA
 
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

SurgiMab Competitors (25)

One of SurgiMab’s 25 competitors is Cellmade, a Private Equity-Backed company based in Ruffieux, France.

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Cellmade Private Equity-Backed Ruffieux, France
Sorrento Therapeutics Formerly VC-backed San Diego, CA
TRexBio Formerly VC-backed South San Francisco, CA
Ambrx Formerly PE-Backed San Diego, CA
Sutro Biopharma Formerly VC-backed South San Francisco, CA
You’re viewing 5 of 25 competitors. Get the full list »

SurgiMab Patents

SurgiMab Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
AU-2016271853-A1 Fluorescent conjugates Active 03-Jun-2015
AU-2016271853-B2 Fluorescent conjugates Active 03-Jun-2015
CA-2986078-A1 Fluorescent conjugates Active 03-Jun-2015
CA-2986078-C Fluorescent conjugates Active 03-Jun-2015
EP-3166606-A1 Fluorescent conjugates Active 03-Jun-2015 A61K49/0058
To view SurgiMab’s complete patent history, request access »

SurgiMab Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

SurgiMab Investors (2)

Investor Name Investor Type Holding Investor Since Participating Rounds
La Synapse Accelerator/Incubator
Abalis Finance Corporation Minority
To view SurgiMab’s complete investors history, request access »

SurgiMab FAQs

  • When was SurgiMab founded?

    SurgiMab was founded in 2010.

  • Where is SurgiMab headquartered?

    SurgiMab is headquartered in Montpellier, France.

  • What is the size of SurgiMab?

    SurgiMab has 6 total employees.

  • What industry is SurgiMab in?

    SurgiMab’s primary industry is Biotechnology.

  • Is SurgiMab a private or public company?

    SurgiMab is a Private company.

  • What is SurgiMab’s current revenue?

    The current revenue for SurgiMab is .

  • How much funding has SurgiMab raised over time?

    SurgiMab has raised $29.2M.

  • Who are SurgiMab’s investors?

    La Synapse and Abalis Finance have invested in SurgiMab.

  • Who are SurgiMab’s competitors?

    Cellmade, Sorrento Therapeutics, TRexBio, Ambrx, and Sutro Biopharma are some of the 25 competitors of SurgiMab.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process